MarketCapExport financials
Sensus Healthcare (SRTS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sensus Healthcare Income Statement 2025-2011 | SRTS
Brief overview of financial results at Sensus Healthcare
The figures are compared over a five-year interval. Revenue at Sensus Healthcare moved from $9.6 million in 2020 to $27.5 million in 2025. The total change was +187%, with a CAGR of approximately 23.5%. Sales grew at a rate typical of a strong expansion phase.
Gross profit changed from 5.2 million dollars to 11.9 million dollars (+126.1%). Cost of revenue developed less favorably than sales and pressured gross profitability. Gross profit as a share of revenue changed from 54.8% to 43.2%. The business retained less gross profit from each unit of revenue.
EBITDA changed from −$7.5 million to −$9.9 million (−31.9%). EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of −78.4% and −36%. The company improved its ability to convert sales into EBITDA.
Net income moved from −$6.8 million at the start to −$7.7 million at the end. Larger losses indicate rising pressure on the business.
The five-year change in capitalization reached +18.5%: from 61.1 million dollars to 72.3 million dollars. Investors assigned a higher value to the business over time.
Overall conclusion
The financial trajectory is weak and requires a cautious interpretation. The financial profile benefits from sales growth and higher operating efficiency. Caution is warranted because of a low EBITDA margin, lower net income and a lower gross margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Sensus Healthcare
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
72.3 M | 76.3 M | 57.2 M | 84.1 M | 119 M | 61.1 M | 67.1 M | 105 M | 71.1 M | 54.7 M | - | - | - | - | - |
Shares |
16.3 M | 16.3 M | 16.3 M | 16.5 M | 16.5 M | 16.3 M | 16.3 M | 14.1 M | 13.2 M | 12 M | - | - | - | - | - |
Historical Prices |
4.43 | 4.68 | 3.52 | 5.1 | 7.22 | 3.86 | 3.54 | 7.41 | 5.16 | 5.25 | - | - | - | - | - |
Net Income |
-7.72 M | 6.65 M | 485 K | 24.2 M | 4.12 M | -6.84 M | -1.7 M | -2.02 M | -3.71 M | -346 K | -237 K | -3.7 M | 108 K | - | - |
Revenue |
27.5 M | 41.8 M | 24.4 M | 44.5 M | 27 M | 9.58 M | 27.3 M | 26.4 M | 20.6 M | 14.8 M | 10.3 M | 5.81 M | 10.5 M | - | - |
Cost of Revenue |
15.6 M | 17.4 M | 10.3 M | 14.9 M | 10.1 M | 4.33 M | 9.71 M | 9.52 M | 6.79 M | 4.97 M | 3.69 M | - | - | - | - |
Gross Profit |
11.9 M | 24.4 M | 14.1 M | 29.6 M | 17 M | 5.25 M | 17.6 M | 16.9 M | 13.8 M | 9.85 M | 6.57 M | 3.76 M | 6.88 M | - | - |
Operating Income |
-10.3 M | 8.09 M | -382 K | 14.8 M | 4.12 M | -8.23 M | -1.97 M | -2.01 M | -3.72 M | -363 K | -221 K | - | - | - | - |
Interest Expense |
683 K | -932 K | -992 K | -380 K | 2 K | 14 K | - | 157 K | 68.9 K | 21.9 K | 17.8 K | - | - | - | - |
EBITDA |
-9.91 M | 8.29 M | -107 K | 15.1 M | 4.73 M | -7.51 M | -1.42 M | -1.35 M | -3.33 M | -25.5 K | 94.3 K | -3.41 M | 392 K | - | - |
Operating Expenses |
22.2 M | 16.3 M | 14.4 M | 14.8 M | 12.9 M | 13.5 M | 19.5 M | 18.9 M | 17.5 M | 10.2 M | 6.8 M | 7.44 M | 6.75 M | - | - |
General and Administrative Expenses |
7.87 M | 7.15 M | 5.16 M | 5.01 M | 4.59 M | 3.99 M | 4 M | 4.12 M | 3.72 M | 3.47 M | 1.59 M | 1.65 M | 1.45 M | - | - |
All numbers in USD currency
Quarterly Income Statement Sensus Healthcare
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
16.5 M | 16.3 M | 16.3 M | 16.3 M | 16.5 M | 16.3 M | 16.3 M | 16.3 M | 16.4 M | 16.3 M | 16.2 M | 16.2 M | 16.4 M | 16.5 M | 16.5 M | 16.5 M | 16.6 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.4 M | 16.4 M | 16.5 M | 16.4 M | 16.4 M | 16.1 M | 16.1 M | 13.8 M | 13.4 M | 13.3 M | 13.5 M | 13.3 M | 13.2 M | 13.2 M | 13.5 M | 13.2 M | 11.2 M | 10.4 M | 10.4 M | 9.88 M | 9.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-2.63 M | -943 K | -1.04 M | -2.57 M | - | 1.22 M | 1.61 M | 2.27 M | - | -1.45 M | -380 K | -1.89 M | - | 1.83 M | 3.52 M | 16.1 M | - | 195 K | -279 K | -1.12 M | - | -1.69 M | -2.57 M | -3.59 M | - | -730 K | 112 K | -2.12 M | - | -458 K | -541 K | -1.13 M | - | -966 K | -764 K | -1.57 M | - | -30.4 K | -351 K | 2.08 K | - | -78.1 K | -88.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
3.39 M | 6.88 M | 7.32 M | 8.34 M | - | 8.84 M | 9.24 M | 10.7 M | - | 3.9 M | 4.53 M | 3.41 M | - | 9.01 M | 12.1 M | 10.3 M | - | 5.52 M | 5.42 M | 3.07 M | - | 1.62 M | 1.18 M | 1.68 M | - | 5.84 M | 7.48 M | 5.44 M | - | 6.33 M | 6.06 M | 5.96 M | - | 4.8 M | 4.97 M | 4.35 M | - | 3.33 M | 3.57 M | 3.04 M | - | 2.11 M | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
2.4 M | 4.17 M | 4.41 M | 3.99 M | - | 3.6 M | 3.82 M | 4 M | - | 1.91 M | 1.91 M | 1.79 M | - | 3.14 M | 3.82 M | 3.19 M | - | 2.32 M | 2.08 M | 1.48 M | - | 948 K | 543 K | 970 K | - | 2 M | 2.54 M | 2.12 M | - | 2.17 M | 2.12 M | 2.02 M | - | 1.58 M | 1.55 M | 1.5 M | - | 1.08 M | 1.25 M | 1.1 M | - | 691 K | 848 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
991 K | 2.71 M | 2.9 M | 4.35 M | - | 5.24 M | 5.42 M | 6.66 M | - | 1.99 M | 2.62 M | 1.62 M | - | 5.87 M | 8.26 M | 7.15 M | - | 3.2 M | 3.34 M | 1.59 M | - | 672 K | 640 K | 709 K | - | 3.84 M | 4.94 M | 3.32 M | - | 4.17 M | 3.94 M | 3.94 M | - | 3.22 M | 3.41 M | 2.85 M | - | 2.25 M | 2.32 M | 1.93 M | - | 1.42 M | 1.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-4.36 M | -2.57 M | -1.94 M | -2.65 M | - | 1.5 M | 1.98 M | 2.89 M | - | -1.9 M | -1.13 M | -2.94 M | - | 2.16 M | 4.57 M | 3.93 M | - | 195 K | -279 K | -1.12 M | - | -2.28 M | -2.57 M | -3.64 M | - | -805 K | 45.5 K | -2.19 M | - | -423 K | -499 K | -1.11 M | - | -965 K | -766 K | -1.59 M | - | -44.2 K | -349 K | 9.59 K | - | -74.3 K | -87.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
125 K | 160 K | -183 K | -184 K | - | 279 K | -209 K | -214 K | - | 319 K | 245 K | -243 K | - | 1 K | 1 K | -1 K | - | 1 K | 1 K | - | - | 2.58 K | 14.4 K | - | - | - | - | - | - | 57.8 K | 65.5 K | 33.4 K | - | 18.9 K | 17.8 K | 6.64 K | - | 972 | 6.23 K | 9.63 K | - | 4.22 K | 1.47 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-4.26 M | -2.47 M | -1.84 M | -2.56 M | - | 1.55 M | 2.01 M | 2.96 M | - | -1.84 M | -1.07 M | -2.87 M | - | 2.21 M | 4.74 M | 4.02 M | - | 667 K | 66 K | -907 K | - | -1.8 M | -2.27 M | -3.48 M | - | -390 K | 327 K | -2.06 M | - | 4.07 K | -265 K | -1.01 M | - | -671 K | -574 K | -1.49 M | - | 209 K | -180 K | 94.4 K | - | 173 K | 80.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
5.35 M | 5.28 M | 4.85 M | 7 M | - | 3.74 M | 3.44 M | 3.78 M | - | 3.88 M | 3.75 M | 4.56 M | - | 3.71 M | 3.69 M | 3.22 M | - | 3.01 M | 3.62 M | 2.7 M | - | 2.95 M | 3.21 M | 4.35 M | - | 4.65 M | 4.89 M | 5.51 M | - | 4.59 M | 4.44 M | 5.05 M | - | 4.18 M | 4.18 M | 4.44 M | - | 2.3 M | 2.67 M | 1.92 M | - | 1.49 M | 1.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.04 M | 1.92 M | 1.99 M | 2.21 M | - | 1.57 M | 1.58 M | 1.58 M | - | 1.51 M | 1.33 M | 1.36 M | - | 1.16 M | 1.13 M | 1.27 M | - | 1.08 M | 1.44 M | 972 K | - | 976 K | 904 K | 1.33 M | - | 957 K | 964 K | 1.01 M | - | 908 K | 914 K | 1.34 M | - | 838 K | 920 K | 1.04 M | - | 790 K | 1.07 M | 686 K | - | 380 K | 369 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Sensus Healthcare (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |